68 filings
8-K
BIOR
Biora Therapeutics Inc
14 Jun 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
BIOR
Biora Therapeutics Inc
7 Jun 24
Amendments to Articles of Incorporation or Bylaws
7:31am
8-K
BIOR
Biora Therapeutics Inc
15 May 24
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:10pm
8-K
BIOR
Biora Therapeutics Inc
2 Apr 24
Entry into a Material Definitive Agreement
4:48pm
8-K
BIOR
Biora Therapeutics Inc
26 Mar 24
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
4:10pm
8-K
3r32k9o 8h0
11 Mar 24
Entry into a Material Definitive Agreement
8:11am
8-K
uolwjlc g430tduw
16 Jan 24
Biora Therapeutics Provides Outlook for 2024
5:20pm
8-K
7lyexst1dk1 tx6i
18 Dec 23
Transaction results in nearly 60% reduction in net debt and brings $16.7 million in new capital for the company
8:06am
8-K
9c0k6j 55lqm
15 Dec 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:25pm
8-K
f7rqiob117i88 9y1rk
1 Dec 23
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination
6:06am
8-K
j6yyf
13 Nov 23
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:10pm
8-K
6r44l
13 Oct 23
Unregistered Sales of Equity Securities
6:04am
8-K
aak5537h17
11 Oct 23
Unregistered Sales of Equity Securities
6:01am
8-K
tqfo0c5
6 Oct 23
Entry into a Material Definitive Agreement
5:19pm
8-K
6tatcuc5oe6f6bf
19 Sep 23
Transaction results in a debt reduction of $50 million for the company
8:06am
8-K
9jx0fxcv2u139rp1ycx
14 Aug 23
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
12:00am
8-K
m99avm1vwle so
15 Jun 23
Departure of Directors or Certain Officers
4:30pm
8-K
ndqcm27havf
14 Jun 23
Biora Therapeutics Announces Closing of $8 Million Registered Direct Offering of Common Stock and Warrants Priced At-the-market Under Nasdaq Rules
4:11pm
8-K
d0fuu
8 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
sv54a0rr4 bnv
15 May 23
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:06pm